Dr. Naseem Amin is currently Senior Vice President of Business Development of Biogen Idec in Cambridge, Massachusetts. Dr. Amin joined Biogen Idec in 2005 from Genzyme Corporation, where he developed a successful track record of identifying and completing partnerships and acquisitions. He most recently served as Head of International Commercial Development. In this position, he had broad responsibility for guiding business development activities in international markets. Dr. Amin also served as Genzyme's Vice President of Business Development and Vice President of Clinical Research. Before joining Genzyme in 1999, Dr. Amin was employed with Baxter Healthcare for seven years where he served as Director of Product Planning and Analysis and in various product management positions.
Dr. Amin has a B.Sc. in biochemistry and an M.D. from Royal Free and University College Medical School at the University of London. He holds an M.B.A. from the Kellogg School of Management, Northwestern University. Dr Amin undertook research in lipid metabolism as a Medical Research Council Fellow at the University of London and Columbia University, New York.
Andrin Oswald is CEO of Novartis Vaccines and Diagnostics, which was created from the acquisition of Chiron Corporation's vaccines and blood testing business. He is also a permanent attendee of the Executive Committee of Novartis. Previously, Dr. Oswald was Chief Executive Officer of Speedel Holding AG and Global Head of Pharmaceutical Development Franchises in the Novartis Pharmaceuticals Division. Dr. Oswald joined Novartis in 2005 as Assistant to the Chairman and CEO. Before his appointment as Head of Development Franchises, he served as Head of the Country Pharma Organization (CPO) and Country President for Novartis in South Korea.
Dr. Oswald joined Novartis from McKinsey & Company, Switzerland, where he was an Associate Principal. Between 2002 and 2003 he was a Delegate of the International Committee of the Red Cross (ICRC) to Nepal.
He holds a doctorate in medicine from the University of Geneva.